Recent Quotes (30 days)

You have no recent quotes
chg | %

BTG plc  

(Public, LON:BTG)   Watch this stock  
Find more results forBTG
680.00
0.00 (0.00%)
Feb 16 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range     -
52 week 554.80 - 784.00
Open     -
Vol / Avg. 0.00/619,869.00
Mkt cap 2,627.96M*
P/E 35.77
Div/yield     -
EPS 0.19*
Shares 386.47M
Beta     -
Inst. own     -
*GBP
May 15, 2018
Full Year 2018 BTG PLC Earnings Release - 8:00am BST - Add to calendar
Apr 3, 2018
BTG PLC Pre-Close Statement Release - 8:00am BST - Add to calendar
Jan 11, 2018
BTG PLC at JPMorgan Healthcare Conference
Dec 7, 2017
BTG PLC Interventional Medicine Seminar
  

Key stats and ratios

Q3 (Sep '17) 2017
Net profit margin 15.50% 5.89%
Operating margin 4.37% 9.68%
EBITD margin - 19.70%
Return on average assets 8.07% 2.73%
Return on average equity 10.80% 3.68%
Employees 1,355 -
CDP Score - C

Address

5 Fleet Place
LONDON, EC4M 7RD
United Kingdom - Map
+44-20-75750000 (Phone)
+44-20-75750010 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing. The Interventional Medicine segment includes oncology, vascular and pulmonology. The segment's products include Beads, TheraSphere, EkoSonic, Varithena and PneumRx Coils for use in the treatment of liver tumors, blood clots, varicose veins and advanced emphysema. The Specialty Pharmaceuticals segment includes CroFab, DigiFab, Voraxaze and Vistogard products for use in the treatment of crotalid envenomation, digoxin toxicity, high-dose methotrexate toxicity and 5-fluorouracil toxicity. The Licensing segment includes Zytiga, Two-Part Hip Cup and Lemtrada products for use in the treatment of advanced prostate cancer, hip replacement and multiple sclerosis.

Officers and directors

Dame Pamela Louise Makin Ph.D. Chief Executive Officer, Executive Director
Duncan Kennedy Chief Financial Officer
Paul Mussenden General Counsel, Head of Strategic Affairs, Company Secretary
Garry Andrew Watts Non-Executive Chairman of the Board
Age: 60
Gregory A. Barrett Non-Executive Director
Age: 63
Anne Thorburn Non-Executive Director
Susan Elizabeth Foden Ph.D. Non-Executive Independent Director
Age: 63
Graham Hetherington Non-Executive Independent Director
Age: 56